Oxymorphol

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Oxymorphol" – news · newspapers · books · scholar · JSTOR (June 2010) (Learn how and when to remove this template message)

Oxymorphol

Clinical data
Other names	4,5α-Epoxy-17-methylmorphinan-3,6,14-triol
ATC code	N02A (WHO)
Pharmacokinetic data
Metabolism	hepatic
Identifiers
IUPAC name (5α)-17-Methyl-4,5-epoxymorphinan-3,6,14-triol
JSmol)	Interactive image
SMILES CN1CC[C@]23c4c5ccc(c4O[C@H]2C(CC[C@]3([C@H]1C5)O)O)O
InChI InChI=1S/C17H21NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,11-12,15,19-21H,4-8H2,1H3/t11?,12-,15+,16+,17-/m1/s1 Y Key:AABLHGPVOULICI-ZOFKVTQNSA-N Y

Oxymorphol is oxymorphone which has been hydrogenated at the 6-position and consists of a mixture of 4,5α-Epoxy-17-methylmorphinan-3,6β,14-triol and 4,5α-Epoxy-17-methylmorphinan-3,6α,14-triol (hydromorphinol).^[1] It is produced by the human body as an active metabolite of oxymorphone and some bacteria as an intermediate in turning morphine into hydromorphone.^[2] It can also be manufactured and is the subject of patents by drug companies looking for new semi-synthetic analgesics and cough suppressants.

A derivative of oxymorphol,